[go: up one dir, main page]

WO2009021521A3 - Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression - Google Patents

Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression Download PDF

Info

Publication number
WO2009021521A3
WO2009021521A3 PCT/DK2008/050198 DK2008050198W WO2009021521A3 WO 2009021521 A3 WO2009021521 A3 WO 2009021521A3 DK 2008050198 W DK2008050198 W DK 2008050198W WO 2009021521 A3 WO2009021521 A3 WO 2009021521A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
depression
gaboxadol
treatment
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2008/050198
Other languages
French (fr)
Other versions
WO2009021521A2 (en
Inventor
Bjarke Ebert
Torsten Meldgaard Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of WO2009021521A2 publication Critical patent/WO2009021521A2/en
Publication of WO2009021521A3 publication Critical patent/WO2009021521A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for the treatment of depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers in said patient is increased or abnormal. The present invention also relates to a method for the treatment of stress-mediated depression comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the level of one or more inflammatory markers is increased or abnormal in said patient. The present invention also relates to a method for the treatment of depression or the amelioration of one or more depressive symptoms comprising administering a therapeutically effective amount of gaboxadol to a patient, wherein the clinical presentation of one or more symptoms of depression are the physiological effect of a general medical condition. Furthermore the present also relates to a method for testing the therapeutic effectiveness of a compound in the treatment of depression or reducing the symptoms of depression comprising measuring the amount of one or more inflammatory markers in a sample from a patient before said compound is administered to the patient and comparing with the amount of said one or more inflammatory markers in a sample from the same patient after administration of said compound to the patient.
PCT/DK2008/050198 2007-08-13 2008-08-12 Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression Ceased WO2009021521A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701154 2007-08-13
DKPA200701154 2007-08-13

Publications (2)

Publication Number Publication Date
WO2009021521A2 WO2009021521A2 (en) 2009-02-19
WO2009021521A3 true WO2009021521A3 (en) 2009-04-23

Family

ID=39798236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050198 Ceased WO2009021521A2 (en) 2007-08-13 2008-08-12 Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression

Country Status (4)

Country Link
AR (1) AR067903A1 (en)
CL (1) CL2008002368A1 (en)
TW (1) TW200920358A (en)
WO (1) WO2009021521A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107209184A (en) * 2014-12-11 2017-09-26 米密德诊断学有限公司 Combinations of markers for diagnosing various infections and methods of use thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2007112C2 (en) * 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
ES2886979T3 (en) 2012-02-09 2021-12-21 Memed Diagnostics Ltd Hallmarks and Determinants for Diagnosing Infections and Methods of Using Them
EP3180621B1 (en) 2014-08-14 2020-04-01 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
CN109804245B (en) 2016-07-10 2022-10-25 米密德诊断学有限公司 Early diagnosis of infection
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CA3071939A1 (en) * 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
MX2021005992A (en) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression.
JP2022514275A (en) 2018-12-17 2022-02-10 オービッド・セラピューティクス・インコーポレイテッド Use of gaboxador for the treatment of non-24-hour sleep-wake disorders
MX2022007715A (en) 2019-12-18 2022-07-19 Ovid Therapeutics Inc GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders
CN113730439A (en) * 2021-09-09 2021-12-03 陕西中鸿瑞康健康管理有限公司 Stem cell factor freeze-dried powder capable of reducing triglyceride and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112786A2 (en) * 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
WO2006053556A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2007093183A2 (en) * 2006-02-14 2007-08-23 H. Lundbeck A/S Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112786A2 (en) * 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
WO2006053556A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2007093183A2 (en) * 2006-02-14 2007-08-23 H. Lundbeck A/S Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107209184A (en) * 2014-12-11 2017-09-26 米密德诊断学有限公司 Combinations of markers for diagnosing various infections and methods of use thereof
CN107209184B (en) * 2014-12-11 2020-04-24 米密德诊断学有限公司 Marker combinations for diagnosing multiple infections and methods of use thereof

Also Published As

Publication number Publication date
WO2009021521A2 (en) 2009-02-19
AR067903A1 (en) 2009-10-28
CL2008002368A1 (en) 2009-01-02
TW200920358A (en) 2009-05-16

Similar Documents

Publication Publication Date Title
WO2009021521A3 (en) Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression
Pignataro et al. nNOS and p-ERK involvement in the neuroprotection exerted by remote postconditioning in rats subjected to transient middle cerebral artery occlusion
Li et al. Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction
ME02662B (en) Low frequency glatiramer acetate therapy
WO2007009539A3 (en) Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
WO2008103993A3 (en) Compositions and methods for treating glycogen storage diseases
EP2331095A4 (en) CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
HK1209633A1 (en) Compositions and methods for treating diabetes
NO20076245L (en) Use of TFPI to treat severe bacterial infections
WO2011041632A3 (en) Combination therapies for the treatment of obesity
JP2013540803A5 (en)
WO2010045417A3 (en) Combination therapies for the treatment of obesity
Giannakopoulos et al. The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: preliminary findings
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
WO2009099642A3 (en) Proteomic analysis of active multiple sclerosis lesions
JP2011513310A5 (en)
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
BR112013025197A2 (en) methods for treating alzheimer's disease and for evaluating the effectiveness of therapy to treat alzheimer's disease
BR112012000773A2 (en) METHOD FOR TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN HUMAN PATIENTS METHOD FOR THE TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN CRITICALLY ILL PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS
Veldhorst-Janssen et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study
Wawrzyniak et al. Comparison of clonidine and midazolam premedication before endoscopic sinus surgery: results of clinical trial
Zhao et al. Long-term administration of simvastatin reduces ventilator-induced lung injury and upregulates heme oxygenase 1 expression in a rat model
KR20120128644A (en) Compounds for use in the treatment of diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08784456

Country of ref document: EP

Kind code of ref document: A2